[225Ac]Ac-DOTATATE Clinical Trials
2 recruitingDrug
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment
SCLC,Extensive Stage
Peking University Cancer Hospital & Institute24 enrolled1 locationNCT07413042
Recruiting
Phase 1
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens
Neuroendocrine Neoplasm
Peking University Cancer Hospital & Institute36 enrolled1 locationNCT06732505